Aspect Biosystems – a biotechnology company advancing the development of bioprinted tissue therapeutics as a new category in regenerative medicine – announced that it has closed a $115 million Series B funding round. This funding round was led by Dimension, a multistage investment firm dedicated to the interface of technology and the life sciences, with participation from existing and new investors, including Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund: A Breakthrough T1D Venture.
This funding builds on Aspect’s recent momentum, including a CA$200 million partnership with the governments of Canada and British Columbia and a partnership with Novo Nordisk focused on diabetes and obesity. The Series B funding round proceeds enable Aspect to advance multiple bioprinted tissue therapeutics towards the clinic with a mission to deliver a new class of cellular medicines and functional cures for people living with serious metabolic and endocrine diseases.
The funds will advance the expansion of Aspect’s industry-leading, full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials.
Along with the financing, Nan Li, Founder & Managing Partner at Dimension, was appointed to the Company’s Board of Directors.
KEY QUOTES:
“I am incredibly proud of the progress our team is making on our mission to develop disease-modifying treatments for people living with serious diseases. We are thrilled to partner with Dimension and this exceptional, mission-aligned investor syndicate. We are grateful for their support as we embark on our next chapter dedicated to transforming patient outcomes for the better.”
– Tamer Mohamed, Founder and CEO, Aspect Biosystems
“Aspect is an embodiment of the multi-disciplinary companies that we believe will define the next chapter of biotech. The company brings together capabilities across tissue engineering, cell therapy, biomaterials, computer vision, and robotics to deliver on the promise of regenerative medicine. We are beyond excited to partner with the Aspect team to advance their programs forward and to build a generational company.”
– Nan Li, Founder & Managing Partner, Dimension
